CN116482390A - Application of Apo-AI detection reagent in evaluating therapeutic effect of allergic rhinitis immunotherapy - Google Patents

Abstract

The invention discloses application of an Apo-AI detection reagent in evaluating the curative effect of immunotherapy of allergic rhinitis. The invention discovers that the Apo-AI can be used as an effective marker for the prognosis diagnosis of the allergic rhinitis immunotherapy, can not only judge the severity of the allergic rhinitis, but also predict and monitor the prognosis of the allergic rhinitis after the immunotherapy, and has high sensitivity and high specificity; the product for judging the severity of allergic rhinitis and carrying out prognosis evaluation can be prepared by quantitatively detecting the reagent of the Apo-AI; the method can be used for distinguishing the severity degree of the allergic rhinitis, is also favorable for prognosis evaluation, further carries out personalized treatment, and finally brings survival benefit to patients.

Description

Application of Apo-AI detection reagent in evaluating therapeutic effect of allergic rhinitis immunotherapy

Technical Field

The invention belongs to the field of biomedicine, and particularly relates to application of an Apo-AI detection reagent in evaluation of curative effect of immunotherapy of allergic rhinitis.

Background

Allergic rhinitis (Allergic rhinitis, AR) is a type II immunological disease mediated by immunoglobulin E, which in turn induces an excessive response to allergens with a incidence of up to 10-30%, especially in pediatric patients. The main symptoms of AR include nasal obstruction, runny nose, itching and sneezing, severely affecting the quality of life of the patient and causing significant economic costs. According to the latest edition of guidelines for allergic rhinitis and its effect on asthma (ARIA guidelines), the main treatment strategies for AR include: avoiding contact with allergen, treatment with drugs such as nasal glucocorticoids and/or antihistamines, specific immunotherapy (AIT) of allergen.

Unlike treatment regimens that avoid short-term control symptoms such as allergen exposure and drug therapy, the inactivated allergen extract in AIT can produce long-term therapeutic effects by repeatedly contacting the patient and gradually increasing the dosage to produce immune tolerance in the body. However, there are cases where a significant portion of allergic rhinitis patients have poor compliance and doubt in AIT treatment, so that self-discontinuation of treatment causes a great deal of waste of social medical resources and loss of personal economy. Thus, the search for biomarkers that monitor the efficacy of AIT for diagnosis is an important point in allergic rhinitis and AIT studies.

Disclosure of Invention

The invention aims to provide a marker for judging the severity of allergic rhinitis and evaluating the curative effect of immunotherapy and application thereof.

The technical scheme adopted by the invention is as follows:

in a first aspect of the invention, there is provided the use of a reagent for quantitative detection of apolipoprotein AI (Apo-AI) in the manufacture of a product for the prognosis evaluation of allergic rhinitis.

In some embodiments of the invention, the reagent comprises a reagent for detecting an apolipoprotein AI using an enzyme linked immunosorbent assay; however, the present invention is not limited thereto, and other methods for detecting the expression level of the apolipoprotein AI may achieve the same effect.

In some embodiments of the invention, the agent comprises an antibody; however, the present invention is not limited thereto, and other agents that can detect the expression level of the apolipoprotein AI can achieve the same effect.

In some embodiments of the invention, the product comprises a reagent, a kit, a test strip or a chip.

In some embodiments of the invention, the sample to be tested is selected from the group consisting of a tissue, a cell, and a fluid.

In some embodiments of the invention, the fluid comprises at least one of blood, lymph, gynecological fluid, cyst fluid, urine, tears, and fluid collected by bronchial lavage and/or peritoneal irrigation.

In some embodiments of the invention, the Apo-AI expression level of the subject is positively correlated with the prognosis of the immunotherapy, the higher the Apo-AI expression level after the immunotherapy, the better its prognosis; can be used for prognosis evaluation of allergic rhinitis immunotherapy.

In some embodiments of the invention, the subject's Apo-AI expression level is inversely related to the severity of allergic rhinitis, and the lower the Apo-AI expression level, the more severe the allergic rhinitis is, which can be used to determine the severity of allergic rhinitis.

In a second aspect of the invention, there is provided a method of determining the severity of allergic rhinitis or assessing the prognosis of immunotherapy comprising the steps of:

(1) Obtaining an apolipoprotein AI expression level in a sample of the subject;

(2) Judging the severity of allergic rhinitis or evaluating the prognosis of immunotherapy according to the expression level of the apolipoprotein AI;

the method is not suitable for diagnosis or treatment of diseases.

In a third aspect of the invention, there is provided a computer readable storage medium storing computer executable instructions for performing the method of the second aspect of the invention.

In a fourth aspect of the invention, there is provided a system for determining the severity of allergic rhinitis or assessing the risk of prognosis of immunotherapy comprising:

a detection device for determining the level of apolipoprotein AI expression in a sample of a subject;

and the output device is used for judging the severity degree of the allergic rhinitis or evaluating the prognosis of the immunotherapy according to the expression level of the apolipoprotein AI.

In some embodiments of the invention, the lower the expression level of the apolipoprotein AI relative to normal, the more severe the allergic rhinitis.

In some embodiments of the invention, the lower the expression level of apolipoprotein AI after immunotherapy relative to before immunotherapy, the worse its prognosis; otherwise, the better the prognosis.

The beneficial effects of the invention are as follows:

the invention discloses an Apo-AI which can be used as an effective marker for prognosis diagnosis of allergic rhinitis immunotherapy, can not only judge the severity of allergic rhinitis, but also predict and monitor prognosis of allergic rhinitis after immunotherapy, and has high sensitivity and high specificity; the product for judging the severity of allergic rhinitis and carrying out prognosis evaluation can be prepared by quantitatively detecting the reagent of the Apo-AI; the method can be used for distinguishing the severity degree of the allergic rhinitis, is also favorable for prognosis evaluation, further carries out personalized treatment, and finally brings survival benefit to patients.

Drawings

FIG. 1 is a graph showing comparison of Apo-AI expression in allergic rhinitis and normal human peripheral blood proteins;

FIG. 2 is a schematic diagram of a study of Apo-AI correlation with allergic rhinitis nasal total symptoms (TNSS);

FIG. 3 is a graph of ROC of Apo-AI versus severity prediction of allergic rhinitis;

FIG. 4 is a graph showing the change in TNSS score before and after treatment for patients with allergic rhinitis;

FIG. 5 shows the variation of Apo-AI concentration in patients with allergic rhinitis before and after receiving immunotherapy;

FIG. 6 is a ROC graph of Apo-AI for prognosis evaluation of allergic rhinitis immunotherapy.

Detailed Description

The conception and the technical effects produced by the present invention will be clearly and completely described in conjunction with the embodiments below to fully understand the objects, features and effects of the present invention. It is apparent that the described embodiments are only some embodiments of the present invention, but not all embodiments, and that other embodiments obtained by those skilled in the art without inventive effort are within the scope of the present invention based on the embodiments of the present invention.

The term "marker" or "biomarker" is an organic biomolecule that is differentially present in a sample taken from a subject in one phenotypic state (e.g., suffering from a disease) as compared to another phenotypic state (e.g., not suffering from a disease). If the average or median level, e.g., expression level, of the biomarker in the different groups is calculated to be statistically significant.

The term "sample" as used herein refers to similar cells or collections of tissue isolated from a subject, as well as tissues, cells, and fluids present within a subject. The term "sample" includes any body fluid (e.g., blood, lymph, gynecological fluid, cyst fluid, urine, tears, and fluid collected by bronchial lavage and/or peritoneal irrigation) or cells from a subject. In one embodiment, the tissue or cell is removed from the subject. In another embodiment, the or cell is present within the subject. Other subject samples include tear drops, serum, cerebrospinal fluid, stool, sputum, and cell extracts. In one embodiment, the biological sample comprises a protein molecule from a test subject. In another embodiment, the biological sample may comprise an mRNA molecule from a test subject or a genomic DNA molecule from a test subject.

The term "detecting" is meant to include detecting the presence or absence of a marker in a sample, quantitatively detecting the amount of a marker in a sample, and/or determining the type of biomarker.

The term "kit" is any article of manufacture (e.g., package or container) comprising at least one reagent, such as a probe, primer or antibody, that specifically detects a marker of the invention, said article of manufacture being marketed, distributed or sold as a unit for performing a method of the invention. In certain embodiments, the kit may comprise a matrix, e.g., a matrix comprising a capture reagent for one or more markers of the invention and/or a capture reagent that binds to one or more markers of the invention. In some embodiments, such kits comprise instructions for determining the level of a marker using mass spectrometry.

The subject or patient may include, but is not limited to, mammals such as cattle, birds, dogs, horses, cats, sheep, pigs, or primates (including humans and non-primates).

Experimental materials:

1. antibody: anti-Apo-AI antibody (manufacturer: R & D system);

2. other materials:

FACS buffer:3% calf serum in PBS; conical tube (BD Labware); buffer (PBS);

3. instrument: BD enzyme-linked immunosorbent device.

Example 1: determination of patient allergic rhinitis severity by detecting Apo-AI expression level

Experimental object and material:

1. the experimental object:

peripheral blood samples of allergic rhinitis patients and normal control groups were obtained from the Guangzhou female child medical center; the morning fasting anticoagulants were collected.

2. The specific experiment:

(1) Collecting peripheral blood, and placing on ice cubes;

(2) Transferring the blood in the step (1) into a 10mL conical tube, adding 15-25 units of heparin per milliliter of blood, and adding an equal volume of buffer solution;

(3) Carrying out anticoagulation centrifugal treatment (at 25 ℃ and at a centrifugal speed of 1600-2000 r/min for 20 min) in the step (2), discarding the precipitate, and reserving the supernatant;

(4) Taking the supernatant in the step (3), and detecting the APO-AI expression level by using an enzyme-linked immunosorbent device.

3. Experimental results:

in this connection, it can be seen from FIG. 1 that Apo-AI expression level in allergic rhinitis patients is significantly reduced compared to normal persons. The correlation coefficient r= -0.64 in fig. 2, which shows that the severity of allergic rhinitis is closely related to the expression level of Apo-AI in the serum of peripheral blood; as can be seen from FIG. 3, by detecting the Apo-AI expression level, the severity of allergic rhinitis can be judged (sensitivity and specificity are 90% and 94% at optimum levels when Apo-AI is 19.89mg/dl, respectively).

Example 2: prognosis of allergic rhinitis immunotherapy by monitoring changes in APO-AI expression levels in patients with allergic rhinitis before and after receiving immunotherapy

Experimental object and material:

1. the experimental object:

peripheral blood samples of patients with allergic rhinitis and peripheral blood samples of the same patient after receiving immunotherapy are obtained from Guangzhou women and children medical centers. The application is directed to a method of immunotherapy for patients with allergic rhinitis by subcutaneous injection (SCIT), comprising the following steps: alogue (mite allergen injection) with indication of allergic diseases induced by inhaled allergen and mediated by IgE, and three years of injection course.

2. The experimental method comprises the following steps: as in example 1.

3. Experimental results:

as can be seen from fig. 4 and 5, APO-AI significantly increased and clinical scores significantly decreased in patients with allergic rhinitis after receiving specific immunotherapy, suggesting that APO-AI can be used as an index for efficacy prediction. As can be seen in FIG. 6, by measuring Apo-AI expression levels, the efficacy of immunotherapy (sensitivity and specificity at optimal levels at 18.64mg/dl for Apo-AI, respectively, 80% and 90%) can be predicted.

Example 3

The application also discloses a reagent for judging the severity of allergic rhinitis and for prognosis, wherein the diagnostic reagent comprises a substance for detecting the expression level of peripheral blood APO-AI, an antibody for detecting peripheral blood APO-AI, and an antibody carrying fluorescent markers.

Therefore, the diagnosis kit designed by the invention can effectively judge the severity of the allergic reaction or monitor the expression level of APO-AI in peripheral blood before and after the immunotherapy of patients with allergic rhinitis, and provides important guiding significance for predicting the AIT curative effect.

In addition, the diagnostic kit designed by the invention can also cooperate with other detection indexes.

Example 4

A method of determining the severity of allergic rhinitis or assessing the prognosis of immunotherapy;

the method comprises the following steps:

(1) Obtaining an apolipoprotein AI expression level in a sample of the subject;

(2) Judging the severity of allergic rhinitis or evaluating the prognosis of immunotherapy according to the expression level of the apolipoprotein AI; the method is not suitable for diagnosis or treatment of diseases.

There is also provided a computer readable storage medium storing computer executable instructions for performing the above method.

Example 5

A system for determining the severity of allergic rhinitis or assessing the risk of prognosis of immunotherapy comprising:

a detection device for determining the level of apolipoprotein AI expression in a sample of a subject;

and an output device for judging the severity of allergic rhinitis or evaluating the prognosis of immunotherapy according to the expression level of the apolipoprotein AI.

The present invention has been described in detail in the above embodiments, but the present invention is not limited to the above examples, and various changes can be made within the knowledge of those skilled in the art without departing from the spirit of the present invention. Furthermore, embodiments of the invention and features of the embodiments may be combined with each other without conflict.

Claims (10)

1. The application of the reagent for quantitatively detecting the apolipoprotein AI in preparing the allergic rhinitis severity judgment and immunotherapy prognosis evaluation products.

2. The use according to claim 1, wherein the reagent comprises a reagent for detecting an apolipoprotein AI by an enzyme linked immunosorbent assay.

3. The use of claim 2, wherein the agent comprises an antibody.

4. The use according to claim 1, wherein the product comprises a reagent, a kit, a test paper or a chip.

5. The use according to any one of claims 1 to 4, wherein the sample to be tested is selected from the group consisting of tissue, cells and body fluids.

6. The use according to claim 5, wherein the fluid comprises at least one of blood, lymph, gynecological fluid, cyst fluid, urine, tears, and fluid collected by bronchial lavage and/or peritoneal irrigation.

7. The use according to claim 1, wherein the Apo-AI expression level of the subject is positively correlated with the prognosis of immunotherapy; preferably, the Apo-AI expression level of the subject is inversely related to the severity of allergic rhinitis.

8. A method of determining the severity of allergic rhinitis or assessing the prognosis of immunotherapy comprising the steps of:

(1) Obtaining an apolipoprotein AI expression level in a sample of the subject;

(2) Judging the severity of allergic rhinitis or evaluating the prognosis of immunotherapy according to the expression level of the apolipoprotein AI;

the method is not suitable for diagnosis or treatment of diseases.

9. A computer-readable storage medium having stored thereon computer-executable instructions for performing the method of claim 8.

10. A system for determining the severity of allergic rhinitis or for assessing the prognosis of immunotherapy, comprising:

a detection device for determining the level of apolipoprotein AI expression in a sample of a subject;

and the output device is used for judging the severity degree of the allergic rhinitis or evaluating the prognosis of the immunotherapy according to the expression level of the apolipoprotein AI.